Brazil's antitrust authority ruled in favor of a pending acquisition of the commercial aviation division of Embraer S.A. by Boeing, without restrictions.
Brazil's health regulator Anvisa said Bharat Biotech's Covaxin did not meet its manufacturing standards. The Brazilian government previously signed a contract to buy 20 million doses. Bharat said in a statement that they would appeal the decision.
Indonesian investigators conclude their probe of the disaster with the release of a 353-page final report. The report states the crash was caused by a combination of flawed software design by Boeing, a failure of Lion Air to ground the jet over issues it had previously experienced, and inappropriate pilot responses to the developing emergency.